# US 2019/0262266 A1 · Formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0262266 A1
- Document ID: US20190262266A1
- Status: Published application
- Kind: A1
- Application number: 16/345,381
- Filed: 2017-10-20
- Published: 2019-08-29
- Earliest claimed: 2016-10-26
- Assignees: Oxy Solutions AS
- Applicants: Oxy Solutions AS
- Inventors: Ingrid MOEN; Hege UGLAND; Mahmood AMIRY-MOGHADDAM; Camilla HAGLERØD
- Web page: https://patentgrep.com/patent/US20190262266A1

## CPC

- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61F 13/00063: {comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic (drug delivery dressings A61K9/70; chemical aspect of the additives A61L15/00)}
- A61F 13/05: specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
- A61K 8/042: {Gels}
- A61K 8/22: Peroxides; Oxygen; Ozone
- A61K 8/731: {Cellulose; Quaternized cellulose derivatives}
- A61K 8/90: Block copolymers (A61K8/89 takes precedence)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61L 15/18: containing inorganic materials
- A61L 15/325: {Collagen}
- A61L 15/44: Medicaments
- A61L 26/0004: {containing inorganic materials}
- A61L 26/0019: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds}
- A61L 26/0023: {Polysaccharides}
- A61L 26/0033: {Collagen}
- A61L 26/0052: {Mixtures of macromolecular compounds}
- A61L 26/0066: {Medicaments; Biocides}
- A61L 26/008: {Hydrogels or hydrocolloids}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/10: Anti-acne agents
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/08: Anti-ageing preparations
- A61K 2800/56: Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The invention provides liquid formulations comprising dissolved oxygen (e.g. 10 mg/L up to 100 mg/L dissolved oxygen), and a substance which is capable of forming a gel upon contact with a body surface or body tissues, wherein said gel is capable of releasing a therapeutically effective amount of dissolved oxygen. The substance capable of forming a gel may be thermogelling and may, for example, comprise a blend of poloxamers. The liquid formulations can be applied to body tissues whereupon they form a gel suitable for the treatment of a compromised tissue, for example a wound (acute or chronic), a burn, a skin disorder (e.g. psoriasis, acne, rosacea, or other dermatological condition such as atopic dermatitis), skin sores, or tissue necrosis. The liquid formulations are also suitable for use in the prevention or treatment of a bacterial biofilm on a body surface, e.g. on the skin. The invention further provides delivery devices (e.g. wound dressings or bandages) having incorporated therein such a liquid formulation or a gel formed therefrom.

## Claims

### Claim 1

A liquid formulation comprising dissolved oxygen and a substance which is capable of forming a gel upon contact with a body surface or body tissues, and wherein said gel is capable of releasing a therapeutically effective amount of dissolved oxygen.

### Claim 2 (depends on 1)

A formulation as claimed in claim 1 which comprises at least about 10 mg/L dissolved oxygen, and preferably up to about 100 mg/L dissolved oxygen, e.g. from about 15 to 70 mg/L, or from about 25 to 50 mg/L dissolved oxygen.

### Claim 3 (depends on 1, 2)

A formulation as claimed in claim 1 or claim 2, wherein said substance which is capable of forming a gel upon contact with a body surface or body tissues comprises at least one in-situ gelling agent.

### Claim 4 (depends on 3)

A formulation as claimed in claim 3, wherein said in-situ gelling agent is thermogelling and capable of forming a gel at body temperature.

### Claim 5 (depends on 4)

A formulation as claimed in claim 4, wherein said in-situ gelling agent is selected from the group consisting of: surface active block copolymers, polysaccharides (e.g. cellulose derivatives, xyloglycan, and chitosan) and N-isopropylacrylamide.

### Claim 6 (depends on 4)

A formulation as claimed in claim 4, wherein said in-situ gelling agent comprises one or more poloxamers.

### Claim 7 (depends on 4)

A formulation as claimed in claim 4, wherein said in-situ gelling agent comprises at least one poloxamer having a thermogelling temperature above about 25° C., e.g. in the range from about 25 to about 37° C.

### Claim 8 (depends on 6, 7)

A formulation as claimed in claim 6 or claim 7, wherein said in-situ gelling agent comprises one or more poloxamers selected from Poloxamer 407, Poloxamer 188, Poloxamer 338, Poloxamer 124, and Poloxamer 237.

### Claim 9 (depends on 8)

A formulation as claimed in claim 8, wherein said in-situ gelling agent comprises Poloxamer 407.

### Claim 10 (depends on 6, 7, 8, 9)

A formulation as claimed in any one of claims 6 to 9 which comprises a blend of poloxamers.

### Claim 11 (depends on 10)

A formulation as claimed in claim 10, wherein said blend comprises two poloxamers in a ratio of from 5:1 to 50:1, preferably from 10:1 to 25:1, e.g. from 10:1 to 15:1.

### Claim 12 (depends on 10, 11)

A formulation as claimed in claim 10 or claim 11, wherein said blend comprises Poloxamer 407 and Poloxamer 188, or Poloxamer 407 and Poloxamer 124.

### Claim 13 (depends on 6, 7, 8, 9, 10, 11, 12)

A formulation as claimed in any one of claims 6 to 12, wherein said poloxamer or blend of poloxamers is present in an amount in the range of from 10 to 30 wt. %, preferably 15 to 25 wt. %. e.g. 16 to 20 wt. % (based on the weight of the formulation).

### Claim 14 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A formulation as claimed in any one of claims 4 to 13 which further comprises one or more thickening agents selected from the following: Carbopol, cellulose derivatives (e.g. hydroxypropyl cellulose or hydroxypropyl methylcellulose), carrageenans, gelatin, pectin, hydrocolloids, alginates, hydrogels, polyurethane, collagen, chitosan, and hyaluronic acid.

### Claim 15

A formulation as claimed in any one of the preceding claims which further comprises one or more bioadhesives, e.g. one or more mucoahesive polymers.

### Claim 16

A formulation as claimed in any one of the preceding claims, wherein the oxygen present in the formulation is dissolved in an aqueous medium which is physiologically tolerable, for example a physiological salt solution (e.g. saline) or water.

### Claim 17

A formulation as claimed in any one of the preceding claims which comprises an oxygenated liquid (e.g. physiological saline or water) obtainable by (e.g. obtained by) a process comprising the following steps:
introducing a pressurized liquid into a piping network to form a flow stream;
injecting gaseous oxygen into the flow stream to produce a mixture of liquid and oxygen bubbles,
providing a linear flow accelerator including a venturi; and
passing the flowing mixture of liquid and gaseous oxygen bubbles through the linear flow accelerator to accelerate the flowing mixture and to subsequently decelerate the flowing mixture to subsonic speed to break up the gaseous oxygen bubbles.

### Claim 18

A formulation as claimed in any one of the preceding claims which further comprises one or more active substances selected from the group consisting of: antibacterial agents, antifungal agents, antiviral agents, antibiotics, growth factors, cytokines, chemokines, nucleic acids, vitamins, minerals, anaesthetics, anti-inflammatory agents, moisturizers, extracellular matrix proteins, enzymes, stem cells from plants, extracts from eggs and eggshells, botanical extracts, fatty acids, and skin penetration enhancers.

### Claim 19 (depends on 18)

A formulation as claimed in claim 18, wherein said antibacterial agent is selected from group consisting of: alcohols, chlorine, peroxides, aldehydes, triclosan, triclocarban, benzalkonium chloride, linezolid, quinupristin-dalfopristin, daptomycin, oritavancin and dalbavancin, quinolones, and moxifloxacin.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A formulation as claimed in any one of claims 1 to 17 which comprises at least one active agent selected from the group consisting of retinoids (e.g. vitamin A, acitretin, isotretinion, tretinion and tazarotene); peroxides (e.g. benzoyl peroxide); antibiotics (e.g. tetracycline, clindamycin, erythromycin, metronidazole, sulfacetamide, doxycycline, oxytetracycline, minocycline, and trimethoprim); hormones (e.g. co-cyprindiol); azelaic acid and derivatives thereof; adapalene; nicotinamide; salicylic acid; corticosteroids, vitamin D and derivatives thereof; antralin, and calcineurin inhibitors.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A formulation as claimed in any one of claims 1 to 17 which comprises at least one wound healing agent, e.g. collagen or chitosan.

### Claim 22

A formulation as claimed in any one of the preceding claims which is a cosmetic formulation and which comprises one or more cosmetically active ingredients selected from the group consisting of peptides, amino acids, hyaluronic acid, hydroxy acids, vitamins or derivatives thereof, retinoids, ceramides, carbamide (urea) and coenzyme Q10.

### Claim 23

A formulation as claimed in any one of the preceding claims which comprises from 50 to 99 wt. % water, preferably from 80 to 99 wt. % water.

### Claim 24

A formulation as claimed in any one of the preceding claims which comprises one or more components which maintain a buffered pH, which maintain osmolality in a range suitable for application to a body surface or body tissues, or which maintain stability of the composition.

### Claim 25

A formulation as claimed in any one of the preceding claims which comprises one or more components selected from the group consisting of: buffers, pH adjusting agents (e.g. sodium hydroxide or hydrochloric acid), osmolality adjusting agents, preservatives (e.g. anti-microbial agents), anti-oxidants, gel forming agents (e.g. Carbopols or cellulose derivatives), fragrances, and coloring agents, preferably a formulation which contains sufficient buffer to provide a pH in the range from 2 to 7, preferably 5 to 5.5, e.g. about 5.1 to about 5.5.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

An oxygen-releasing gel obtainable by allowing the liquid formulation as claimed in any one of claims 1 to 25 to gel.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A formulation or oxygen-releasing gel as claimed in any one of claims 1 to 26 for use in medicine or for use as a medicament.

### Claim 28 (depends on 27)

A formulation or oxygen-releasing gel for use as claimed in claim 27 in the treatment of a compromised tissue, for example a wound (acute or chronic), a burn, a skin disorder (e.g. psoriasis, acne, rosacea, or other dermatological condition such as atopic dermatitis), skin sores, or tissue necrosis.

### Claim 29 (depends on 27)

A formulation or oxygen-releasing gel for use as claimed in claim 27 in the treatment of bacterial or fungal infections of the skin, for example cellulitis, infections in chronic wounds, gas gangrene, necrotizing fasciitis (infection by enterococcus, enterobacteriacea, clostridium, B. fragilis, streptococcus, pyogenis), or a fungal infection associated with mucorales or aspergilus.

### Claim 30 (depends on 27)

A formulation or oxygen-releasing gel for use as claimed in claim 27 in the prevention or treatment of a bacterial biofilm on a body surface, preferably on an external body surface, e.g. on the skin.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A delivery device (e.g. a wound dressing or bandage) having incorporated therein a liquid formulation as claimed in any one of claims 1 to 25 or an oxygen-releasing gel as claimed in claim 26.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method for the treatment of a compromised body surface or body tissue of a mammalian subject (e.g. a human), said method comprising:
(i) applying to said surface or tissue an effective amount of a liquid formulation as claimed in any one of claims 1 to 25; and
(ii) allowing said formulation to set to form a gel.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

Use of a liquid formulation as claimed in any one of claims 1 to 25 in the manufacture of a medicament for use in a method for the treatment of a compromised body surface or body tissue of a mammalian subject (e.g. a human).

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A kit for use in the treatment of a compromised body surface or body tissue of a mammalian subject (e.g. a human), the kit comprising:
(a) a sealed container or package containing a liquid formulation as claimed in any one of claims 1 to 25;
(b) a delivery device, e.g. a wound dressing or bandage; and
optionally
(c) instructions for use of components (a) and (b) in the topical treatment of a compromised tissue.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method of cosmetic treatment performed on a mammalian subject (e.g. a human), said method comprising the step of administering to the surface of the skin of said subject a liquid formulation as claimed in any one of claims 1 to 25.

### Claim 36 (depends on 35)

A method as claimed in claim 35 for improving or otherwise enhancing the appearance of the skin, for example in softening the skin, or in reducing any one of the following: hyper-pigmentation, roughness, dryness, fine lines and wrinkles of the skin.
